What are Arkema's main competitors?
Arkema operates in the global specialty chemicals and advanced materials sector, competing against major multinational chemical enterprises. Its primary international competitors include companies such as BASF SE, Dow Inc., DuPont de Nemours, Evonik Industries, Solvay, and LANXESS. These corporate giants vie for market share across high-performance engineering plastics, industrial coatings, adhesive technologies, and specialized chemical formulations utilized in automotive, construction, and electronics industries worldwide.
Related FAQs
Equity research analysts tracking Arkema stock generally assign mixed to moderately positive consensus ratings, balancing its long-term positioning in specialty materials and eco-friendly battery components against cyclical industrial demand.
Arkema S.A. is a major French multinational specialty chemicals and advanced materials manufacturer.
No, BPCL and Indian Oil are completely separate, independent public sector undertakings (PSUs) owned by the Government of India, operating as fierce competitors in the nation's downstream petroleum refining and fuel marketing sector.
Arkema, a prominent global specialty chemicals and advanced materials company headquartered near Paris, France, was created in 2004 through a massive corporate restructuring of the chemical branch of the French energy conglomerate Total.
Arkema S.A., a global leader in specialty chemicals and advanced materials, is headquartered in Colombes, France.
Arkema is a global specialty chemicals and advanced materials manufacturer producing a diverse portfolio of high-performance solutions for industrial applications.
The corporate brand name Arkema is a carefully crafted portmanteau and trade name established when major chemical assets were reorganized, blending linguistic elements that evoke chemistry, advanced materials, and enterprise strength.
Arkema sells a broad portfolio of advanced specialty chemicals, high-performance engineering polymers, industrial coating resins, adhesives, and fluorochemical products to corporate clients across the globe.
Market strategists frequently point to sectors experiencing temporary regulatory headwinds, cyclical downturns, or shifts in institutional investor sentiment—such as traditional regional banking, selective biotechnology, or certain energy sub-sectors...
Arkema structures its dividend policy as a core component of its overall shareholder return framework, aiming to provide regular, predictable, and progressively increasing financial rewards to investors.
Arkema is not a United States enterprise, maintaining its corporate headquarters, legal domicile, and primary operational roots in Colombes, France.
Armstrong Bank has served its communities as a family-owned financial institution for over a century, tracing its operational history back to its founding in 1909 in Muskogee County, Oklahoma.
Determining whether Arkema represents a favorable purchase or an asset to sell involves analyzing consensus brokerage opinions, which typically cluster around a neutral hold to moderate buy range.
Equity research analysts covering Arkema S.A.
Ascendis Pharma A/S, a biopharmaceutical company focused on developing a pipeline of innovative therapies utilizing its proprietary TransCon technology platform, maintains a specialized global workforce of approximately 1,500 employees.
Arkema S.A. shares trade on Euronext Paris at valuations reflecting conditions in the global specialty chemicals and advanced materials sectors.
Assessing whether Arkema shares are undervalued depends on valuation modeling comparing current market trading prices against estimated future cash flows and peer industry multiples.
Equity research analysts project stable, multi-year growth prospects for Arkema, driven by its strategic transformation into a pure-play specialty materials manufacturer.
Arkema operates as a fully public corporate entity, listed and traded prominently on Euronext Paris under the ticker symbol AKE.